Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318270 | 0.82 | CHRNB2 (0.56) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL29321182 | 0.81 | SCN9A (0.40) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL14473816 | 0.76 | CHRNB2 (0.60) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL19446091 | 0.73 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL13135282 | 0.73 | HPGD (0.57) | HPGD | |
| SCHEMBL13335329 | 0.72 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL15716501 | 0.72 | CHRNB2 (0.58) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL19405964 | 0.72 | CHRNB4 (0.61) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL10141670 | 0.72 | KDM1A (0.42) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL21325266 | 0.72 | CHRNB4 (0.42) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | CHRNB2 2532/4885CHRNA4 2107/4885KDM4E 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.